Pluri
$2.37
14
+$0.07+3.22% Friday 20:00
Statistics
Day High
2.58
Day Low
2.35
52W High
5.92
52W Low
2.3
Volume
5,149
Avg. Volume
-
Mkt Cap
23.86M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Dividends
0%Dividend Yield
Nov 23
$0.01
Mar 23
$0.01
Dec 16
$0.02
Jun 16
$0.01
Nov 15
$0.06
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A
Earnings
14MayExpected
Expected EPS
-0.66
Actual EPS
-0.55
Financials
-1,690.34%Profit Margin
Unprofitable2.67MRevenue
-45.17MNet Income
People Also Follow
This list is based on the watchlists of people on Stock Events who follow PLUR. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Twilio
TWLO
Mkt Cap28.52B
SentinelOne
S
Mkt Cap6.39B
Crowdstrike
CRWD
Mkt Cap168.87B
Zscaler
ZS
Mkt Cap29.32B
Okta
OKTA
Mkt Cap16.17B
Palo Alto Networks
PANW
Mkt Cap211.33B
Fortinet
FTNT
Mkt Cap98.12B
Check Point Software Technologies
CHKP
Mkt Cap13.9B
Cloudflare
NET
Mkt Cap76.41B
About
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the muscle recovery following surgery for hip fracture; and Phase I/II clinical trial for the treatment of steroid-refractory graft versus host disease in collaboration with Tel Aviv Sourasky Medical Center, as well as completed a Phase II clinical trial for the treatment of acute respiratory distress syndrome associated with COVID-19 and a Phase I clinical trial for incomplete recovery following bone marrow transplantation. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation; and a solution for the treatment of acute radiation syndrome through its collaboration in the United States with the National Institutes of Health and the U.S. Department of Defense. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Show more...
CEO
Mr. Yaacov Yanay
Employees
106
Country
United States
ISIN
US72942G2030
Listings
0 Comments
Share your thoughts
FAQ
What is Pluri stock price today?▼
The current price of PLUR is $2.37 USD — it has increased by +3.22% in the past 24 hours. Watch Pluri stock price performance more closely on the chart.
What is Pluri stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Pluri stocks are traded under the ticker PLUR.
Is Pluri stock price growing?▼
PLUR stock has fallen by -5.79% compared to the previous week, the month change is a -29.03% fall, over the last year Pluri has showed a -48.73% decrease.
What is Pluri market cap?▼
Today Pluri has the market capitalization of 23.86M
When is the next Pluri earnings date?▼
Pluri is going to release the next earnings report on September 23, 2026.
What were Pluri earnings last quarter?▼
PLUR earnings for the last quarter are -0.55 USD per share, whereas the estimation was -0.66 USD resulting in a +16.67% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Pluri revenue for the last year?▼
Pluri revenue for the last year amounts to 2.67M USD.
What is Pluri net income for the last year?▼
PLUR net income for the last year is -45.17M USD.
How many employees does Pluri have?▼
As of May 26, 2026, the company has 106 employees.
In which sector is Pluri located?▼
Pluri operates in the Health & Wellness sector.
When did Pluri complete a stock split?▼
The last stock split for Pluri was on April 01, 2024 with a ratio of 1:8.
Where is Pluri headquartered?▼
Pluri is headquartered in Haifa, United States.